Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Cellular Adaptation IV: Dysplasia and Metaplasia01:24

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.

The Journal of clinical investigation·2026
Same author

Mapping and engineering the human cell-cell interactome.

Nature biotechnology·2026
Same author

A Phase 1b Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

Blastic plasmacytoid dendritic cell neoplasm

John K Lee1, Gary Schiller

  • 1Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Clinical Advances in Hematology & Oncology : H&O
|March 9, 2012
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

Related Experiment Videos

Last Updated: May 24, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014